Session

Back to Programme Overview

Prostate cancer: Impact of MRI on biopsies

Poster Session 37

  • Location:
    Room Munich, North Hall (Level 1)
  • Chairs:
     C. Arsov, Düsseldorf (DE)
     O. Rouviere, Lyon, Cedex (FR)
     J. Walz, Marseille (FR)
  • Aims and objectives of this session

    This session will highlight the optimal use of MRI for the stratification of men undergoing prostatic biopsies

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 493
Clinical outcome following a low-suspicious multiparametric prostate MRI or benign MRI-targeted biopsies for prostate cancer detection: A 3-year follow-up study of men with prior negative transrectal ultrasound guided biopsies

By: Boesen L.1, Nørgaard N.1, Løgager V.2, Thomsen H.2

Institutes: 1Herlev University Hospital, Dept. of Urology, Herlev, Denmark, 2Herlev University Hospital, Dept. of Radiology, Herlev, Denmark

494
Multi-parametric magnetic resonance imaging combined with prostate-specific antigen velocity can predict the probability of prostate cancer in patients after initial negative biopsy

By: Song G., Huang C., Ji G., Zhou L.

Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

495
Evaluation of negative predictive value of multiparametric MRI for prostate cancer: Retrospective analysis after 5 years of clinical experience

By: Barchetti G.1, Del Monte M.1, Salvo V.1, Grompone M.1, Sciarra A.2, Panebianco V.1

Institutes: 1Sapienza University of Rome, Dept. of Radiology, Rome, Italy, 2Sapienza University of Rome, Dept. of Urology, Rome, Italy

496
PSA-density based patient selection for MRI-targeted prostate biopsy could reduce unnecessary biopsy procedures in men on active surveillance for low-grade prostate cancer

By: Alberts A.1, Roobol M.1, Drost F-J.2, Van Leenders G.3, Bokhorst L.1, Bangma C.1, Schoots I.2

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands

* 497
Improving accuracy of prostate cancer risk prediction in prostate biopsy naïve patients with suspicious PSA and/or digital rectal examination through implementation of multiparametric MRI obtained parameters

By: Musch M.1, Roggenbuck U.2, Malik-Patsalis A.B.3, Lehmann N.2, Ebel T.4, Koch J-A.3, Krege S.1, Kroepfl D.1

Institutes: 1Kliniken Essen-Mitte, Dept. of Urology, Paediatric Urology and Urologic Oncology, Essen, Germany, 2University of Duisburg-Essen, Institute For Medical Informatics, Biometry and Epidemiology, Essen, Germany, 3Kliniken Essen-Mitte, Dept. of Diagnostic and Interventional Radiology, Essen, Germany, 4Zentrum Für Pathologie Essen-Mitte, Centre For Pathology, Essen, Germany

498
Combined clinical parameters and multiparametric MRI for advanced risk modeling of prostate cancer - patient-tailored risk stratification can reduce unnecessary biopsies

By: Radtke J.P.1, Bonekamp D.2, Kesch C.1, Freitag M.2, Alt C.3, Celik K.1, Distler F.4, Roth W.5, Wieczorek K.6, Duensing S.1, Roethke M.2, Teber D.1, Schlemmer H-P.2, Hohenfellner M.1, Hadaschik B.1

Institutes: 1University Hospital Heidelberg, Dept. of Urology, Heidelberg, Germany, 2German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany, 3University Hospital Düsseldorf, Dept. of Interventional and Diagnostic Radiology, Düsseldorf, Germany, 4Paracelsus University Nürnberg, Dept. of Urology, Nürnberg, Germany, 5University Medicine Mainz, Dept. of Pathology, Mainz, Germany, 6University of Heidelberg, Dept. of Pathology, Heidelberg, Germany

499
Added value of pre-biopsy prostate multiparametric MRI in biopsy-naïve patients: Preliminary results of the MRI-FIRST trial

By: Rouviere O.1, Puech P.21, Renard Penna R.19, Claudon M.10, Roy C.2, Mege Lechevallier F.30, Decaussin-Petrucci M.31, Rabilloud M.28, Schott Pethelaz A.M.29, Dubreuil Chambardel M.1, Magaud L.32, Cros F.1, Barry Delongchamps N.16, Boutier R.13, Bratan F.1, Brunelle S.4, Camparo P.25, Colin P.24, Correas J.M.17, Cornélis F.6, Cornud F.15, Descotes J.L.26, Eschwege P.11, Fiard G.26, Fendler J.P.12, Habchi H.18, Hallouin P.9, Khairoune A.17, Lang H.3, Lebras Y.6, Malavaud B.14, Moldovan P.1, Mottet N.18, Mozer P.20, Nevoux P.8, Pagnoux G.1, Pasticier G.7, Portalez D.14, Potiron E.8, Timsit M-O.34, Villers A.23, Walz J.5, Colombel M.27, Ruffion A.33, Crouzet S.27, Lemaitre L.22, Grenier N.6

Institutes: 1Hôpital Edouard Herriot, Dept. of Imaging , Lyon, France, 2CHU De Strasbourg, Dept. of Radiology, Strasbourg, France, 3CHU De Strasbourg, Dept. of Urology, Strasbourg, France, 4Institut Paoli-Calmettes, Dept. of Imaging , Marseille, France, 5Institut Paoli-Calmettes, Dept. of Surgery Oncology, Marseille, France, 6CHU Pellegrin, Dept. of Radiology, Bordeaux, France, 7CHU Pellegrin, Dept. of Urology, Bordeaux, France, 8Clinique Nantes Atlantis, Dept. of Urology, Saint Herblain, France, 9Cabinet De Radiologie, Nantes, France, 10CHRU Nancy-Brabois, Dept. of Radiology, Nancy, France, 11CHRU Nancy-Brabois, Dept. of Urology, Nancy, France, 12Centre Hospitalier St Joseph St Luc, Dept. of Urology, Lyon, France, 13Centre Hospitalier St Joseph St Luc, Dept. of Radiology, Lyon, France, 14IUCT-ONCOPOLE, Dept. of Uro-Oncology, Toulouse, France, 15Hôpital COCHIN, Dept. of Radiology, Paris, France, 16Hôpital COCHIN, Dept. of Urology, Paris, France, 17Groupe Hospitalier Necker Enfants Malades, Dept. of Radiology, Paris, France, 18CHU Hôpital Nord, Dept. of Urology, St Etienne, France, 19UPMC APHP – Hôpitaux Tenon-Pitié Salpétrière, Dept. of Imaging , Paris, France, 20UPMC APHP – Hôpital Pitié Salpétrière, Dept. of Urology, Paris, France, 21Université Lille, CHU De Lille, Dept. of Radiology, Lille, France, 22Univ. Lille, CHU De Lille, Dept. of Genito-Urinary Radiology , Lille, France, 23Univ. Lille, CHU De Lille, Dept. of Urology, Lille, France, 24Hôpital Privé La Louvrière, Ramsay Générale De Santé, Dept. of Urology, Lille, France, 25Centre De Pathologie, Amiens, France, 26CHU De Grenoble, Dept. of Urology, Grenoble, France, 27Hôpital Edouard Herriot, Dept. of Urology, Lyon, France, 28Centre Hospitalier Lyon Sud, Dept. of Biostatic Service, Pierre Bénite, France, 29Université Lyon 1, Dept. of Training and Research in Human Biology, Lyon, France, 30Hôpital Edouard Herriot, Dept. of Pathological Anatomy and Cytology, Lyon, France, 31Centre Hospitalier Lyon Sud, Laboratoire D’anatomie Et Cytologie Pathologiques, Pierre Bénite, France, 32Hospices Civils De Lyon, Medical Information Division, Research Evaluation and Scientific Publication Support, Lyon, France, 33Centre Hospitalier Lyon Sud, Dept. of Urology, Pierre Bénite, France, 34Hôpital Européen Georges Pompidou, Dept. of Urology, Paris, France

500
A randomized controlled trial to assess and compare the outcomes of AI-US-CT guided biopsy, transrectal ultrasound guided 12-core systematic biopsy, and mpMRI assisted 12-core systematic biopsy

By: Xie L-P., Wang X., Zheng X-Y., Liu B., Li J-F., Wang S.

Institutes: 1st Affiliated Hospital, College of Medicine, Zhejiang University, Dept. of Urology, Hangzhou, China

501
Value of magnetic resonance imaging in population-based prostate cancer screening: Comparison of 3 biopsy strategies in the 5th screening round of the ERSPC Rotterdam

By: Alberts A.1, Schoots I.2, Drost F-J.2, Bokhorst L.1, Van Leenders G.3, Dwarkasing R.2, Barentsz J.4, Schröder F.1, Bangma C.1, Roobol M.1

Institutes: 1Erasmus MC, Dept. of Urology, Rotterdam, The Netherlands, 2Erasmus MC, Dept. of Radiology, Rotterdam, The Netherlands, 3Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands, 4Radboud MC, Dept. of Radiology, Nijmegen, The Netherlands

502
A prospective randomized study comparing standard prostate biopsy and a new diagnostic path with MRI and fusion biopsy: Results after two years

By: Porpiglia F., Mele F., Manfredi M., De Luca S., Checcucci E., Bertolo R., Garrou D., Cattaneo G., Amparore D., Bollito E., Russo F., Gned D., De Pascale A., Cirillo S., Fiori C.

Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy

V44
Focal therapy with HIFU FocalOne device with MRI target fusion biopsy by KOELIS

By: Potiron E., Nevoux P., Rousseau T., Le Goguic G., Lacoste J.

Institutes: Clinique Urologique Nantes Atlantis, Nantes, France

503
Transcriptome wide analysis of MRI-targeted biopsy and matching surgical specimens from high-risk prostate cancer patients treated with radical prostatectomy

By: Hadaschik B.1, Takha M.2, Radtke J.P.1, Bonekamp D.3, Du Plessis M.2, Buerki C.2, Erho N.2, Ong K.2, Davicioni E.2

Institutes: 1University of Heidelberg, Medical Faculty Heidelberg, Dept. of Urology, Heidelberg, Germany, 2GenomeDx Biosciences Inc., Research and Development, Vancouver, Canada, 3German Cancer Research Center, Dept. of Radiology, Heidelberg, Germany

504
Prostate MRI for predicting capsular invasion prior to robot-assisted radical prostatectomy. Lesson learned after 400 cases

By: Porpiglia F., Manfredi M., Mele F., Bertolo R., Amparore D., Cattaneo G., Garrou D., Checcucci E., Bollito E., Volante M., Veltri A., De Pascale A., Gned D., Russo F., Regge F., Regge D., Cirillo S., Fiori C.

Institutes: San Luigi Hospital, Dept. of Urology, Turin, Italy

505
Concordance between biopsy and radical prostatectomy Gleason score: Evaluation of determinants in a large-scale study of patients undergoing RALP in Belgium

By: Soenens C.1, Ameye F.1, De Kuyper P.1, De Coster G.2, Van Damme N.2, Vandervorst L.2, Quackels T.3, Roumeguère T.3, Joniau S.4, Van Cleynenbreugel B.4

Institutes: 1Az Maria Middelares, Dept. of Urology, Ghent, Belgium, 2Belgian Cancer Registry, Belgian Cancer Registry, Brussels, Belgium, 3Erasmus Hospital, Dept. of Urology, Brussels, Belgium, 4University Hospital of Leuven, Dept. of Urology, Leuven, Belgium

506
Does the inclusion of non-index lesions at biopsy improve our ability to predict adverse pathologic outcomes at radical prostatectomy? Implications for targeted plus systematic biopsy schemes

By: Gandaglia G.1, Bandini M.1, Dell’Oglio P.1, Fossati N.1, Pellegrino F.1, Fallara G.1, Zaffuto E.1, Bravi C.A.1, Nocera L.1, Damiano R.2, Freschi M.3, Montironi R.4, Montorsi F.1, Briganti A.1

Institutes: 1Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, 2Magna Graecia University, Dept. of Urology, Catanzaro, Italy, 3Vita-Salute University San Raffaele, Dept. of Pathology, Milan, Italy, 4Polytechnic University of The Marche Region, Section of Pathological Anatomy, Ancona, Italy